Skip to main content
SpringerLink
Log in

Pharmacokinetics and Pharmacodynamics of Gastrointestinal Drugs

  • Chapter
  • First Online:
Sex/Gender-Specific Medicine in the Gastrointestinal Diseases

  • 700 Accesses

Abstract

Pharmacokinetics (PK) refer to the process by which a drug is absorbed, distributed, metabolized, and excreted from the route of administration to the systemic circulation, and the process by which a drug that arrives at the site of action shows efficacy is called pharmacodynamics (PD). Various factors such as the patient’s age, weight, disease status, concomitant drugs, genotype, and sex can cause individual differences in PK and PD.

Due to the structural, morphological, and physiological differences between men and women, the drug absorption, distribution, metabolism, and excretion (ADME) processes may also be different, resulting in different drug concentrations. In addition, drug effects can vary between sexes due to the differences in disease pathogenesis or drug receptors that the drug acts upon.

Since the sex differences in PK and PD vary by drug, a drug-specific/disease-specific approach is required, and this chapter will illustrate these differences using gastrointestinal drugs such as proton pump inhibitors (PPIs) and antivirals as examples.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Derendorf H, Schmidt S. Rowland and Tozer’s clinical pharmacokinetics and pharmacodynamics: concepts and applications. 5th ed. Philadelphia: Wolters Kluwer; 2020.

    Google Scholar 

  2. Tamargo J, Rosano G, Walther T, Duarte J, Niessner A, Kaski JC, et al. Gender differences in the effects of cardiovascular drugs. Eur Heart J Cardiovasc Pharmacother. 2017;3:163–82.

    Article  CAS  Google Scholar 

  3. Franconi F, Brunelleschi S, Steardo L, Cuomo V. Gender differences in drug responses. Pharmacol Res. 2007;55:81–95.

    Article  CAS  Google Scholar 

  4. Anderson GD. Gender differences in pharmacological response. Int Rev Neurobiol. 2008;83:1–10.

    Article  Google Scholar 

  5. Whitley H, Lindsey W. Sex-based differences in drug activity. Am Fam Physician. 2009;80:1254–8.

    PubMed  Google Scholar 

  6. Vukovich RA, Brannick LJ, Sugerman AA, Neiss ES. Sex differences in the intramuscular absorption and bioavailability of cephradine. Clin Pharmacol Ther. 1975;18:215–20.

    Article  CAS  Google Scholar 

  7. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2009;48:143–57.

    Article  CAS  Google Scholar 

  8. Chu T. Gender differences in pharmacokinetics. US Pharm. 2014;39:40–3.

    Google Scholar 

  9. Kalibala J, Pechere-Bertschi A, Desmeules J. Gender differences in cardiovascular pharmacotherapy-the example of hypertension: a mini review. Front Pharmacol. 2020;11:564.

    Article  CAS  Google Scholar 

  10. Franconi F, Carru C, Malorni W, Vella S, Mercuro G. The effect of sex/gender on cardiovascular pharmacology. Curr Pharm Des. 2011;17:1095–107.

    Article  CAS  Google Scholar 

  11. Schwartz JB. The current state of knowledge on age, sex, and their interactions on clinical pharmacology. Clin Pharmacol Ther. 2007;82:87–96.

    Article  CAS  Google Scholar 

  12. Li S, Xu M, Li H, Du J, Li W. Pharmacokinetic properties of oral lafutidine tablets and the effect of food on its pharmacokinetics in healthy Chinese subjects. Adv Ther. 2016;33:1704–14.

    Article  CAS  Google Scholar 

  13. Nazir S, Iqbal Z, Ahmad L, Ahmad S. Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects. Pak J Pharm Sci. 2016;29:887–94.

    CAS  PubMed  Google Scholar 

  14. Wang H, Ou N, Lang L, Shi R, Hu P, Jiang J. Pharmacokinetics and pharmacodynamics of intravenous ilaprazole in healthy subjects after single ascending doses. Xenobiotica. 2016;46:1133–41.

    Article  CAS  Google Scholar 

  15. Kim YS, Kim N, Kim GH. Sex and gender differences in gastroesophageal reflux disease. J Neurogastroenterol Motil. 2016;22:575–88.

    Article  Google Scholar 

  16. El-Serag H, Becher A, Jones R. Systematic review: persistent reflux symptoms on proton pump inhibitor therapy in primary care and community studies. Aliment Pharmacol Ther. 2010;32:720–37.

    Article  CAS  Google Scholar 

  17. Ruigomez A, Johansson S, Wernersson B, Fernandez Cantero O, Garcia Rodriguez LA. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response. Scand J Gastroenterol. 2012;47:751–61.

    Article  CAS  Google Scholar 

  18. Lundell L, Hatlebakk J, Galmiche JP, Attwood SE, Ell C, Fiocca R, et al. Long-term effect on symptoms and quality of life of maintenance therapy with esomeprazole 20 mg daily: a post hoc analysis of the LOTUS trial. Curr Med Res Opin. 2015;31:65–73.

    Article  CAS  Google Scholar 

  19. Helgadóttir H, Metz DC, Lund SH, Gizurarson S, Jacobsen EI, Asgeirsdóttir GA, et al. Study of Gender differences in proton pump inhibitor dose requirements for GERD: a double-blind randomized trial. J Clin Gastroenterol. 2017;51:486–93.

    Article  Google Scholar 

  20. Gong C, Agbokponto JE, Yang W, Simpemba E, Zheng X, Zhang Q, et al. Pharmacokinetics of levosulpiride after single and multiple intramuscular administrations in healthy Chinese volunteers. Acta Pharm Sin B. 2014;4:402–7.

    Article  Google Scholar 

  21. Xu M, Zhou Y, Ni Y, He X, Li H, Sattar H, et al. Tolerability and pharmacokinetic comparison of oral, intramuscular, and intravenous administration of levosulpiride after single and multiple dosing in healthy Chinese volunteers. Clin Ther. 2015;37:2458–67.

    Article  CAS  Google Scholar 

  22. Parkman HP, Carlson MR, Gonyer D. Metoclopramide nasal spray reduces symptoms of gastroparesis in women, but not men, with diabetes: results of a phase 2B tandomized study. Clin Gastroenterol Hepatol. 2015;13:1256–63.e1251.

    Article  CAS  Google Scholar 

  23. Jin R, Fossler MJ, McHutchison JG, Howell CD, Dowling TC. Population pharmacokinetics and pharmacodynamics of ribavirin in patients with chronic hepatitis C genotype 1 infection. AAPS J. 2012;14:571–80.

    Article  CAS  Google Scholar 

  24. Wu LS, Rower JE, Burton JR Jr, Anderson PL, Hammond KP, Baouchi-Mokrane F, et al. Population pharmacokinetic modeling of plasma and intracellular ribavirin concentrations in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother. 2015;59:2179–88.

    Article  CAS  Google Scholar 

  25. Jen JF, Glue P, Gupta S, Zambas D, Hajian G. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 2000;22:555–65.

    Article  CAS  Google Scholar 

  26. Muir AJ, Bornstein JD, Killenberg PG. Atlantic Coast Hepatitis Treatment G. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med. 2004;350:2265–71.

    Article  CAS  Google Scholar 

  27. Conjeevaram HS, Fried MW, Jeffers LJ, Terrault NA, Wiley-Lucas TE, Afdhal N, et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. Gastroenterology. 2006;131:470–7.

    Article  CAS  Google Scholar 

  28. U.S. Food and Drug Administration. Ribavirin Label. 2015. https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/021511s029lbl.pdf. Accessed 26 July 2020.

  29. Narciso-Schiavon JL, Schiavon Lde L, Carvalho-Filho RJ, Sampaio JP, Batah PN, Barbosa DV, et al. Gender influence on treatment of chronic hepatitis C genotype 1. Rev Soc Bras Med Trop. 2010;43:217–23.

    Article  Google Scholar 

  30. Mensing S, Eckert D, Sharma S, Polepally AR, Khatri A, Podsadecki TJ, et al. Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials. Br J Clin Pharmacol. 2017;83:527–39.

    Article  CAS  Google Scholar 

  31. Koch KM, Palmer JL, Noordin N, Tomlinson JJ, Baidoo C. Sex and age differences in the pharmacokinetics of alosetron. Br J Clin Pharmacol. 2002;53:238–42.

    Article  CAS  Google Scholar 

  32. Chaudhary DV, Patel DP, Shah JV, Shah PA, Sanyal M, Shrivastav PS. Application of a UPLC-MS/MS method for the analysis of alosetron in human plasma to support a bioequivalence study in healthy males and females. Biomed Chromatogr. 2015;29:1527–34.

    Article  CAS  Google Scholar 

  33. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials. Clin Ther. 2008;30:884–901.

    Article  CAS  Google Scholar 

  34. Al-Huniti N, Chapel S, Xu H, Bui KH, Sostek M. Population pharmacokinetics of naloxegol in a population of 1247 healthy subjects and patients. Br J Clin Pharmacol. 2016;81:89–100.

    Article  CAS  Google Scholar 

  35. Eldon MA, Kugler AR, Medve RA, Bui K, Butler K, Sostek M. Safety, tolerability, and pharmacokinetics of multiple ascending doses of naloxegol. Clin Pharmacol Drug Dev. 2015;4:442–8.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea

    Seonghae Yoon

Authors
  1. Seonghae Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Seonghae Yoon .

Editor information

Editors and Affiliations

  1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Korea (Republic of)

    Nayoung Kim

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Yoon, S. (2022). Pharmacokinetics and Pharmacodynamics of Gastrointestinal Drugs. In: Kim, N. (eds) Sex/Gender-Specific Medicine in the Gastrointestinal Diseases. Springer, Singapore. https://doi.org/10.1007/978-981-19-0120-1_28

Download citation

  • DOI: https://doi.org/10.1007/978-981-19-0120-1_28

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-19-0119-5

  • Online ISBN: 978-981-19-0120-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation